Proud to wholeheartedly endorse my dear friend @montypal for the ASCO Board! An exceptional leader, generous mentor, and true champion of women in oncology and young investigators globally! I can think of no one better suited to advance ASCO’s mission globally! Month has been instrumental in guiding me since I started as faculty and I have always benefited from his generosity and kindness personally. You have my vote, Monty! @HemOncWomenDocs @NehaVapiwala @crisbergerot @OncoAlert @NazliDizman @DrChoueiri @neerajaiims @PGrivasMDPhD @TDorffOnc @TiansterZhang @DrRanaMcKay @JasmineKambojMD @AshleySumrallMD @IbiayiMD

👏👏👏 @curijoey @shilpaonc @NazliDizman @PBarataMD @GregoryAVidal

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: bit.ly/4BvJVrG

Congrats @Dr_SabyGeorge ! really great collaborative work, we all know IIT have multiple challenges, and this signal is so promising that requires further investigation. Congrats for leading these efforts

These data are very relevant in advanced RCC, in this age of immunotherapy. Thanks to all the co-investigators, coordinators, the respective institutional ethics committees at 5 centers and above all, to the patients. @deepak_kilari @LenAppleman @DrVaishampayan @EHeath4100

Now out in #JCO! 👇 ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide with Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer. Read the article. bit.ly/4zRcWMR #ProstateCancer #pcsm

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU

Excited to see my friend @PGrivasMDPhD running for the ASCO Nominating Committee! Petros brings dedication, generosity, and a deep commitment to our oncology community. He has my enthusiastic support - please consider giving him yours! @tompowles1 @brian_rini @neerajaiims

Such a proud moment to see my friend and mentor @neerajaiims leading another practice-changing trial. Great news for patients. Let's improve genetic testing rates and find patients suitable for biomarker-based therapies! @ASCO @urotoday

ASCO colleagues, please vote! A great slate of ASCO candidates, including the great @montypal. Monty has helped my career immensely - a leader in GU oncology, outstanding researcher, and generous mentor who understands ASCO’s mission and the responsibility of Board service. He has my wholehearted support. Please vote! @neerajaiims @DrChoueiri @tompowles1 @brian_rini @DrRanaMcKay

Honored to serve our incredible @SWOG #GUonc committee w/ my fellow patient advocates, Darrell & Joël. It’s empowering to use our lived experience to help create clinical trials for our fellow patients. Years ago, it was @PeggyZuckerman who was my voice when #PAPMET S1500 was created. I’m humbly grateful that brilliant study team led by @montypal not only saved my life with this research, but that it led to a CR that allows me to give back. Thank you to @SupportingSWOG for making it possible for patients to participate in research advocacy!

⚡️ New meta-analysis confirming the benefit of perioperative immune-based strategies in cisplatin-eligible MIBC (NIAGARA + KEYNOTE-B15). Meaningful EFS and OS gains — but the two regimens are not interchangeable. Patient selection matters. @vmollica7 @fmassari79 @giannatempopatr @shilpaonc pubmed.ncbi.nlm.nih.gov/4286… #BladderCancer #MIBC #GUOncology

Exciting opportunity for Urology & med onc trainees and practicing physicians👉Elevate your clinical and leadership skills at the @PCFnews Leadership Academy! 📍Santa Monica | Dec 3–5, 2026 ✅ Expert faculty mentoring ✅ Formal certification ✅ Travel & hotel covered 👉Apply: bit.ly/4dyRWlv @urotoday

Renal cancer highlights #ESMO26 1) Final OS data for LS11 (Lenvatinib/belzutifan vs cabo in pretreated disease) & final OS for KN564 (adjuvant pembro vs placebo) @DrChoueiri 2) 1st line triplet data for Len/pembo/bel vs Len/pembro/CTLA4 vs Len/pembro @brian_rini Press release shows it’s negative. Triplets appear hard in RCC. 3) New monotherapy data for Ivanesimab (VEGF/PD1) and more data. Combination trials to follow 4) A randomised phase II of metastasis-directed therapy +/- pembro @DrIacovelli Finally phase 2 data of ENPP3/CD3 T cell engager @montypal @myESMO @Annals_Oncology @OncoAlert

ARTICLE: Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study by Daniel D. Shapiro, Daniel F. Roadman...Edwin Jason Abel et al buff.ly/YkBggnv @d_shapiro1 EDITORIAL: Risk-informed Stratification and Counseling for Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma by Jeffrey Y. Zhong, Hannah M. Garcia, and Pedro C. Barata buff.ly/WZMzQmI @JeffreyYZhong, @PBarataMD EDITORIAL: Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning by Francesco Rossia, Massimiliano Depalma, Bernardo Rocco, Riccardo Autorino buff.ly/EisXD7a @Dr_FraRossi, @bernardorocco73, @ricautor We thank all the authors for your valuable contributions! @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @DaveDandrea @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Great success for our GU community in NorthEast Ohio! Thanks @shilpaonc for partnership. We are already thinking of GU onc 2027!! Stay tuned!

1/5 New in @UrolOncol: consensus statements from the IKCS North America 2025 Think Tank on trials for rare kidney cancers. 46 experts. 20 statements. One message: move beyond pooled “non-clear cell” #kidneycancer primary analyses: authors.elsevier.com/a/1nmZc…

Nearly every presentation delivered new data, evolving perspectives, and game-changing insights into prostate cancer care. What a difference two years makes in theranostics! Heading into #ProsTIC26, I’ll admit I found myself asking some tough questions: Are there already too many scientific meetings? Has the field really shifted that much? Do we actually need another ProsTIC? Standing in Melbourne last week alongside over 500 participants from around 25 countries, the answer was a resounding yes. The pace of progress since #ProsTIC24 is mind-blowing. The week proved that bringing so many different disciplines into one room is essential for pushing patient outcomes forward. From quite intense clinical debates, learning from patient experience, discussing new scientific approaches like Terbium-161 and Lead-212, to an unforgettable 80s-themed celebration, the momentum in this space seems unstoppable. Check out the video below for a recap of the highlights - and get ready, because with the way this field is expanding, #ProsTIC28 can't come soon enough! @PCF_Science @PCFA @PeterMacCC

🚨 VIRO 2026 starts tomorrow! I am honored to serve as Chair of VIRO 2026 – Global Voices in Renal Oncology, taking place virtually on September 10–11. Join us for two days of expert presentations, important discussions, and global collaboration focused on the latest advances in kidney cancer care. Don’t miss this opportunity—register today and join us live online tomorrow! 🌍 Fully virtual 📺 Live on YouTube and X 👉 Register now: oncodaily.com/project/o-seri… I look forward to welcoming you to VIRO 2026! #VIRO2026 #RenalOncology #KidneyCancer #OncoDaily #Cancer #Oncology